Abstract: A composition, containing a pepper component, a curcumin-cyclodextrin mixture and a mixture of fruits, vegetables and spices.

Abstract: The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions.

Abstract: The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions.

Abstract: The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions.

Abstract: The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions.

Abstract: The present invention provides a method of inhibiting at least one of allergic asthma, allergic rhinitis and atopic. The present invention further provides a method for the reduction, prevention or treatment of allergy like symptoms in a subject.

Abstract: The present invention provides a method of inhibiting at least one of allergic asthma, allergic rhinitis and atopic. The present invention further provides a method for the reduction, prevention or treatment of allergy like symptoms in a subject.

Abstract: Pharmaceutical compositions for treating neoplastic disorders and uses thereof are provided. Said pharmaceutical compositions comprise stabilized chlorite solutions (e.g. WFIO) and a fluoropyrimidine, 5-FU, or a 5-FU prodrug (e.g. capecitabine, doxifluridine, UFT, S-1, or BOF-A2). The use of the above stabilized chlorite solution in combination with a fluoropyrimidine dramatically improves the quality of life index (QOL) of a patient undergoing cancer chemotherapy. Cancers that can be treated include cancers of the pancreas, gastrointestinal, head, neck, and breast.

Abstract: Methods of determining clinical outcomes in patients suffering from a pathological condition or syndrome are provided. Levels of intracellular gene expression are measured from a clinical sample provided by the patient, and the levels are compared to reference levels. Deviations from reference levels are predictive of clinical outcomes, for example, disease progression or response to therapeutic intervention.

Abstract: The invention relates to a bunged vessel of thermoplastic synthetic material having bungs arranged in the head end area. At least one of the bungs is arranged laterally outwardly of the center of the head end with the interior wall surface thereof generally flush with the interior wall surface of the cylindrical part of the shell of the vessel.

Abstract: The invention provides a stabilized activated oxygen in matrix of chlorite ions and pharmaceutical compositions containing this stabilized activated oxygen. The stabilized activated oxygen is present in the form of a solution. The medication can be used for the treatment of skin diseases or wound healing disorders.

Abstract: A plastic container-cover assembly comprises (a) a container body having a top opening; (b) a first shoulder provided at the outside of the container close to the edge of its opening; (c) a cover for said opening; (d) an outside flange provided on said cover and extending downwardly and then at a sharp angle outwards, the outwardly pointed portion of the flange in the closed position abutting the upper side of said first container shoulder; (e) a hinge provided in proximity to the outer edge of said outwardly pointed portion of said flange; (f) at least two rigid closure flaps linked by said hinge to said flange for swinging from an open to a closed position; (g) a first ledge formed on said flap and, in the closed position, extending inwards and abutting against the bottom side of said first container shoulder; (h) a second, when closed, inwardly extending ledge formed on said flap spaced from said first ledge; (i) a second shoulder formed on the outside of said container spaced from said first shoulder, and